Jane T Seto

List of Publications by Year
in descending order

33 papers	1,752 citations	279798 23 h-index	434195 31 g-index
41 all docs	41 docs citations	41 times ranked	2338 citing authors

#	Article	IF	Citations
1	The MMAAS Project: An Observational Human Study Investigating the Effect of Anabolic Androgenic Steroid Use on Gene Expression and the Molecular Mechanism of Muscle Memory. Clinical Journal of Sport Medicine, 2023, 33, e115-e122.	1.8	2
2	Response to the United Nations Human Rights Councilâ€™s Report on Race and Gender Discrimination in Sport: An Expression of Concern and a Call to Prioritise Research. Sports Medicine, 2021, 51, 839-842.	6.5	8
3	Integrating Transwomen and Female Athletes with Differences of Sex Development (DSD) into Elite Competition: The FIMS 2021 Consensus Statement. Sports Medicine, 2021, 51, 1401-1415.	6.5	15
4	ACTN3 genotype influences skeletal muscle mass regulation and response to dexamethasone. Science Advances, 2021, 7, .	10.3	7
5	LATE BREAKING NEWS E-POSTER PRESENTATION. Neuromuscular Disorders, 2020, 30, S170.	0.6	0
6	Sport and exercise genomics: the FIMS 2019 consensus statement update. British Journal of Sports Medicine, 2020, 54, 969-975.	6.7	37
7	Association Between Hematological Parameters and Iron Metabolism Response After Marathon Race and ACTN3 Genotype. Frontiers in Physiology, 2019, 10, 697.	2.8	7
8	Cullin-3â€“dependent deregulation of ACTN1 represents a pathogenic mechanism in nemaline myopathy. JCI Insight, 2019, 4, .	5.0	14
9	Î‘lpha-Actinin-3â€™s Role in the Genetic Control of Muscle Strength and Performance. , 2019, , 323-343.		1
10	The Effect of ACTN3 Gene Doping on Skeletal Muscle Performance. American Journal of Human Genetics, 2018, 102, 845-857.	6.2	17
11	Is evolutionary loss our gain? The role of ACTN3 p.Arg577Ter (R577X) genotype in athletic performance, ageing, and disease. Human Mutation, 2018, 39, 1774-1787.	2.5	50
12	Exploring the relationship between Î±-actinin-3 deficiency and obesity in mice and humans. International Journal of Obesity, 2017, 41, 1154-1157.	3.4	9
13	Androgen Action via the Androgen Receptor in Neurons Within the Brain Positively Regulates Muscle Mass in Male Mice. Endocrinology, 2017, 158, 3684-3695.	2.8	26
14	Analysis of theACTN3heterozygous genotype suggests that Î±-actinin-3 controls sarcomeric composition and muscle function in a dose-dependent fashion. Human Molecular Genetics, 2016, 25, 866-877.	2.9	35
15	Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Human Molecular Genetics, 2016, 25, R9-R17.	2.9	62
16	NF1 is a critical regulator of muscle development and metabolism. Human Molecular Genetics, 2014, 23, 1250-1259.	2.9	40
17	Î±-Actinin-3 deficiency alters muscle adaptation in response to denervation and immobilization. Human Molecular Genetics, 2014, 23, 1879-1893.	2.9	26
18	Therapy of Genetic Disorders: Novel Therapies for Duchenne Muscular Dystrophy. Current Pediatrics Reports, 2014, 2, 102-112.	4.0	28

#	Article	IF	Citations
19	ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling. Journal of Clinical Investigation, 2013, 123, 4255-4263.	8.2	113
20	Animal Models of Muscular Dystrophy. Progress in Molecular Biology and Translational Science, 2012, 105, 83-111.	1.7	37
21	Gene Replacement Therapies for Duchenne Muscular Dystrophy Using Adeno-Associated Viral Vectors. Current Gene Therapy, 2012, 12, 139-151.	2.0	30
22	Î±-Actinin-3 deficiency is associated with reduced bone mass in human and mouse. Bone, 2011, 49, 790-798.	2.9	37
23	The effect of Î±-actinin-3 deficiency on muscle aging. Experimental Gerontology, 2011, 46, 292-302.	2.8	47
24	Properties of extensor digitorum longus muscle and skinned fibers from adult and aged male and female Actn3 knockout mice. Muscle and Nerve, 2011, 43, 37-48.	2.2	26
25	Deficiency of Î±-actinin-3 is associated with increased susceptibility to contraction-induced damage and skeletal muscle remodeling. Human Molecular Genetics, 2011, 20, 2914-2927.	2.9	95
26	Therapeutic approaches to muscular dystrophy. Human Molecular Genetics, 2011, 20, R69-R78.	2.9	92
27	Validation of an automated computational method for skeletal muscle fibre morphometry analysis. Neuromuscular Disorders, 2010, 20, 540-547.	0.6	25
28	Î±-Actinin-3 deficiency results in reduced glycogen phosphorylase activity and altered calcium handling in skeletal muscle. Human Molecular Genetics, 2010, 19, 1335-1346.	2.9	73
29	Mutations in Contactin-1, a Neural Adhesion and Neuromuscular Junction Protein, Cause a Familial Form of Lethal Congenital Myopathy. American Journal of Human Genetics, 2008, 83, 714-724.	6.2	72
30	Limbâ€“girdle muscular dystrophy: Diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscular Disorders, 2008, 18, 34-44.	0.6	99
31	A gene for speed: contractile properties of isolated whole EDL muscle from an Î±-actinin-3 knockout mouse. American Journal of Physiology - Cell Physiology, 2008, 295, C897-C904.	4.6	75
32	An Actn3 knockout mouse provides mechanistic insights into the association between Â-actinin-3 deficiency and human athletic performance. Human Molecular Genetics, 2008, 17, 1076-1086.	2.9	266
33	Loss of ACTN3 gene function alters mouse muscle metabolism and shows evidence of positive selection in humans. Nature Genetics, 2007, 39, 1261-1265.	21.4	278